Johnson & Johnson Stock Slides After MedTech Miss -- WSJ
Dow Jones2026/10/13 15:06By Alex Janin
Shares of Johnson & Johnson dropped more than 5% Tuesday morning after the company reported weaker-than-expected results from its medical devices division.
"We are clear on where MedTech performance needs to improve," said J&J's chief financial officer Joe Wolk on the earnings call, citing its cardiovascular and surgery units. Its $16.6 billion acquisition of heart-pump maker Abiomed has been a drag.
Pharmaceuticals were the company's primary growth driver. But older medicines are behind some of the sales bump, rather than newer and more strategically important products, wrote Guggenheim analyst Vamil Divan.
The stock was on pace Tuesday for its largest decrease on a percentage basis since April 2025.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
October 13, 2026 11:06 ET (15:06 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Nikkei Average Index gains expand to 2.78%
Surprise! Japan intervened in the forex market three times this summer, selling a record 154 trillion yen in three days
Japan has confirmed that it intervened in the foreign exchange market three times this summer, buying yen to support the exchange rate, corroborating earlier market reports. This included the first joint intervention with the United States to support the yen in nearly thirty years.
UBS CEO warns: A Democratic sweep could slow down AI capacity building, valuation concerns are "very important"
UBS CEO Ermotti stated that the U.S. midterm elections may slow down AI capacity building and that the valuations are questionable; he also warned of persistent inflation and the risk of contagion in the European bond market.
Crypto prices
More
